分阶段三联疗法联合益生菌对幽门螺旋杆菌胃炎患者的效果及其对COX-2和E-cadherin的影响  

Study on the effect of phased triple therapy combined with probiotics in patients with Helicobacter pylori gastritis and its impact on COX-2 and E-Cadherin

作　　者：朱晓 ZHU Xiao(Department of Polyclinic,the 29th Research Institute of China Electronics Technology Group Corporation,Chengdu 610036,Sichuan,China)

机构地区：[1]中国电子科技集团公司第二十九研究所综合门诊部,四川成都610036

出　　处：《川北医学院学报》2024年第5期692-695,共4页Journal of North Sichuan Medical College

摘　　要：目的:探讨分阶段三联疗法联合益生菌在幽门螺旋杆菌(Hp)胃炎患者中的治疗效果及其对环氧化酶2(COX-2)和钙粘附蛋白E(E-cadherin)的影响。方法:选取92例幽门螺旋杆菌胃炎患者作为研究对象,按照治疗方式不同分为对照组与观察组,每组各46例。对照组采用分阶段三联疗法治疗;观察组联合益生菌治疗,两组患者均治疗两个疗程(31 d为1个疗程),比较两组患者胃肠激素、C反应蛋白(CRP)、白细胞计数(WBC)、COX-2、E-cadherin、Hp根除率及不良反应发生情况。结果:干预后,两组患者PGⅠ、PGⅡ及G-17均降低,且观察组低于对照组(P<0.05);PGR水平均升高,且观察组高于对照组(P<0.05);干预后,两组炎症反应减轻及COX-2、E-cadherin水平均降低,且观察组低于对照组(P<0.05);疗程完毕后,观察组Hp根除率高于对照组(P<0.05);两组不良反应发生率无统计学差异(P>0.05)。结论:分阶段三联疗法联合益生菌用于Hp胃炎患者中,能调节胃肠激素,降低炎症反应和COX-2、E-cadherin水平,可提高Hp根除率,且药物安全性较高,值得推广应用。Objective:To investigate the therapeutic effect of phased triple therapy combined with probiotics in Helicobacter pylori(Hp)gastritis patients and its influence on cycoperoxidase 2(COX-2)and cadherin E(E-cadherin).Methods:A total of 92 patients with helicobacter pylori gastritis were selected and divided into two groups according to different treatment methods,with 46 cases in each group.The control group was treated with three-phase triple therapy,and the observation group was combined with probiotics.Both groups were treated for 2 courses of treatment(31 days for 1 course).Gastrointestinal hormone,C-reactive protein(CRP),white blood cell count(WBC),COX-2,E-cadherin,Hp clearance and adverse reactions were compared between the two groups.Results:Gastrointestinal hormone was improved after 2 courses of intervention in both patients groups.PGⅠ,PGⅡand G-17 in observation group were lower than those in control group(P<0.05).PGR level was higher than that of control group(P<0.05).After 2 courses of intervention,the inflammatory response was alleviated and the levels of COX-2 and E-cadherin were decreased in both groups.The levels of CRP,WBC,COX-2 and E-cadherin in observation group were lower than those in control group(P<0.05).The eradication rate of Hp in the observation group was higher than that in the control group(P<0.05).There was no statistical difference in adverse reactions between the two groups(P>0.05).Conclusion:Three-phase triple therapy combined with probiotics in Hp gastritis patients can regulate gastrointestinal hormones,reduce inflammatory response,COX-2,E-cadherin levels,and increase Hp clearance,and the drug is safe,worthy of promotion and application.

关 键 词：幽门螺旋杆菌胃炎 益生菌 分阶段三联疗法 环氧化酶2 钙粘附蛋白E 

分 类 号：R452[医药卫生—治疗学]